Astellas has reported efficacy and safety data for isavuconazole in the Phase III SECURE study for patients with invasive Fungal...
Pfizer Inc has. announced that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
The FDA has approved Noxafil (posaconazole) injection (18 mg/ mL), from Merck, a new formulation of the Fungal Infection treatment...
GSK plc and Scynexis Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC)
What are the problems with evolving invasive fungal strains, and what is being done to combat them? Read our original article investigating the emerging burden of anti-fungal resistance.
Positive topline data from the SECURE Phase III study of isavuconazole, from Astellas/Basilea Pharma, achieved its primary objective in demonstrating...
Treatment of mild cases of distal and lateral subungual onychomycoses caused by dermatophytes, yeasts and moulds; treatment is limited to 2 nails.
Mayne Pharma Group announced that the FDA has approved the New Drug Application (NDA) for Tolsura (SUBA-itraconazole) 65mg capsules. Tolsura...
The FDA has approved a New Drug Application for Luzu (luliconazole) Cream, 1%, from Valeant Pharmaceuticals International, for the topical...
Basilea Pharmaceutica has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of isavuconazole for...